Samchundang Shakes Market Trust

Editor's Note Behind the controversy over Samchundang Pharmaceutical's dramatic stock price fluctuations lies a chronic and structural problem: the excessive ambition of KOSDAQ-listed technology companies and loopholes in the market system. This crisis, which wiped out tens of trillions of won in market capitalization in an instant and threw investors into panic, is particularly painful because it has seriously damaged the credibility that the K-bio industry has painstakingly built. We examine whether the technological blueprints Samchundang Pharmaceutical presented to investors are realistic, and what institutional shortcomings led to this situation. ③Regulatory Gaps, Persistent Risks Another issue highlighted by the Samchundang Pharmaceutical incident is the common practice of concealing crucial det

Editor's Note Behind the volatility in Samchundang Pharm's stock price lies a web of chronic and structural issues, including the excessive ambition of KOSDAQ-listed technology companies and loopholes in the market system. The recent incident, which wiped out tens of trillions of won in market capitalization in an instant and sent investors into a panic, is particularly painful as it has seriously damaged the trust assets that the K-bio industry has painstakingly built. This article examines whether the technological blueprints Samchundang Pharm presented to investors are truly realistic, and what institutional deficiencies contributed to this situation. ③Regulatory Loopholes, Persistent Risks Beyond the validity or consistency of the technology itself, another issue that emerged from the cont

Editor's NoteThe controversy surrounding the sharp fluctuations in Samchundang Pharmaceutical's stock price is deeply rooted in the chronic and structural issues of the KOSDAQ-listed technology companies' excessive ambitions and the shortcomings of the market system. This incident, which erased tens of trillions of won in market capitalization in an instant and threw investors into panic, is particularly painful as it has seriously undermined the trust assets that the K-Bio industry has painstakingly built. This article examines whether the technological blueprint presented by Samchundang Pharmaceutical to investors is realistic, and what institutional shortcomings triggered this crisis. ③Regulatory Loopholes, Lingering Risks Questions are mounting over the technological feasibility and regulato